Wu Jingjing, Fu Jiaping, Zhang Mingzhi, Liu Delong
Department of Oncology, The first Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Department of Hematology, Shaoxing People's Hospital, Shaoxing, Zhejiang Province, China.
J Hematol Oncol. 2015 Sep 4;8:104. doi: 10.1186/s13045-015-0195-4.
Targeted therapy has been the forefront of cancer treatment. Cancer immunotherapy is the most recent focus. In addition, novel immunotherapeutics targeting B cell receptor signaling (e.g., ibrutinib), T cell receptor ( e.g., CART19), and NK cells (e.g., AFM13) are being developed. This review summarized the new development in blinatumomab (MT103/MEDI-538), a first-in-class bispecific T engager (BiTE) antibody against CD19/CD3 in patients with relapsed/refractory precursor B cell acute lymphoid leukemia.
靶向治疗一直处于癌症治疗的前沿。癌症免疫疗法是最近的焦点。此外，针对B细胞受体信号传导（如伊布替尼）、T细胞受体（如CART19）和自然杀伤细胞（如AFM13）的新型免疫疗法正在研发中。本综述总结了复发/难治性前体B细胞急性淋巴细胞白血病患者中首个双特异性T细胞衔接器（BiTE）抗体——博纳吐单抗（MT103/MEDI-538）针对CD19/CD3的新进展。
